Citi Pharma Ltd
Citi Pharma Ltd operates in Pharmaceuticals.
Market Cap & Net Worth: Citi Pharma Ltd (CPHL)
Citi Pharma Ltd (KAR:CPHL) has a market capitalization of $2.55K (PKRs711.04K) as of March 18, 2026. Listed on the KAR stock exchange, this Pakistan-based company holds position #47045 globally and #179 in its home market, demonstrating a 4.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Citi Pharma Ltd's stock price PKRs73.19 by its total outstanding shares 9715 (9.71K).
Citi Pharma Ltd Market Cap History: 2021 to 2026
Citi Pharma Ltd's market capitalization history from 2021 to 2026. Data shows growth from $933.42 to $2.55K (28.55% CAGR).
Index Memberships
Citi Pharma Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Karachi All Share
KSI
|
$3.34 Million | 0.07% | #149 of 448 |
Weight: Citi Pharma Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Citi Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Citi Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CPHL by Market Capitalization
Companies near Citi Pharma Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Citi Pharma Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #3465 globally with a market cap of $3.69 Billion USD ( ₩5.41 Trillion KRW).
- Mezzion Pharma Co.Ltd (KQ:140410): Ranked #6393 globally with a market cap of $1.27 Billion USD ( ₩1.86 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #7113 globally with a market cap of $1.05 Billion USD ( ₩1.54 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #7795 globally with a market cap of $890.75 Million USD ( ₩1.30 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3465 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $3.69 Billion | ₩739000.00 |
| #6393 | Mezzion Pharma Co.Ltd | KQ:140410 | $1.27 Billion | ₩89200.00 |
| #7113 | ST Pharm Co.Ltd | KQ:237690 | $1.05 Billion | ₩153400.00 |
| #7795 | Oscotec Inc | KQ:039200 | $890.75 Million | ₩54900.00 |
Citi Pharma Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Citi Pharma Ltd's market cap moved from $933.42 to $ 2.55K, with a yearly change of 28.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | PKRs2.55K | -13.49% |
| 2025 | PKRs2.95K | +24.21% |
| 2024 | PKRs2.37K | +209.54% |
| 2023 | PKRs766.69 | +21.62% |
| 2022 | PKRs630.37 | -32.47% |
| 2021 | PKRs933.42 | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Citi Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.55K USD |
| MoneyControl | $2.55K USD |
| MarketWatch | $2.55K USD |
| marketcap.company | $2.55K USD |
| Reuters | $2.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.